Evidence map›Paper›PMID 36186227›Full record

ArticleInternational cancer conference journal2022

Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation.

Takafumi Fukushima, Jun Teishima, Keisuke Goto, Kenshiro Takemoto, Yohei Sekino, Kohei Kobatake, Kenichiro Ikeda, Tetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue and 2 more

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Takafumi FukushimaDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8551 Japan.
Jun TeishimaDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8551 Japan.
Keisuke GotoDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8551 Japan.
Kenshiro TakemotoDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8551 Japan.
Yohei SekinoDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8551 Japan.
Kohei KobatakeDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8551 Japan.
Kenichiro IkedaDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8551 Japan.
Tetsutaro HayashiDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8551 Japan.
Kazuhiro SentaniDepartment of Molecular Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Naohide OueDepartment of Molecular Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Takao HinoiDepartment of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima, Japan.
Nobuyuki HinataDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minamiku, Hiroshima, 734-8551 Japan.
Hiroshima University · JPHiroshima University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is the most predominant type of kidney cancer in adults and comprises several histological subtypes. Among them, the chromophobe RCC (ChRCC) with sarcomatoid differentiation is a rare subtype, and its therapeutic strategy remains unclear. Hence, to provide more information on effective therapeutic strategies against ChRCC, we report two cases of ChRCC with sarcomatoid differentiation treated with nivolumab monotherapy or ipilimumab-nivolumab combination therapy. One patient was treated with nivolumab monotherapy after the failure of sunitinib, while the other was treated with ipilimumab-nivolumab combination therapy as a first-line option. The therapeutic strategies adopted in both cases were effective, but the patients experienced immune-related adverse events such as interstitial nephritis and colitis. Thus, our report indicates that immune checkpoint therapy is effective for ChRCCs with sarcomatoid differentiation.

Indexed as

Chromophobe renal cell carcinomaImmune checkpoint inhibitorSarcomatoid differentiation

Identifiers

PMID36186227
PMCPMC9522941
OpenAlexW4287958420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.